Editas Medicine, Inc. (FRA:8EM)
Germany
· Delayed Price · Currency is EUR 2.061
+0.087 (4.38%)
At close: Dec 5, 2025
Editas Medicine Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 165.65 | 131.54 | 123.65 | 141.52 | 203.52 | 139.68 | Upgrade
|
| Short-Term Investments | - | 138.37 | 199.46 | 202.75 | 296.33 | 262.43 | Upgrade
|
| Cash & Short-Term Investments | 165.65 | 269.91 | 323.11 | 344.27 | 499.85 | 402.11 | Upgrade
|
| Cash Growth | -37.51% | -16.46% | -6.15% | -31.12% | 24.31% | -12.04% | Upgrade
|
| Accounts Receivable | 8.13 | 16.27 | 10.19 | 5.15 | 0.27 | 6.05 | Upgrade
|
| Receivables | 8.13 | 16.27 | 10.19 | 5.15 | 0.27 | 6.05 | Upgrade
|
| Prepaid Expenses | 3.11 | 3.14 | 7.53 | 7.34 | 7.2 | 10.93 | Upgrade
|
| Total Current Assets | 176.89 | 289.32 | 340.83 | 356.75 | 507.31 | 419.09 | Upgrade
|
| Property, Plant & Equipment | 21.87 | 47.05 | 45.71 | 59.22 | 43.29 | 39.15 | Upgrade
|
| Long-Term Investments | - | - | 104.02 | 93.1 | 120.07 | 109.66 | Upgrade
|
| Other Long-Term Assets | 2.99 | 5.22 | 8.59 | 5.25 | 6.81 | 4.7 | Upgrade
|
| Total Assets | 201.75 | 341.59 | 499.15 | 514.32 | 677.48 | 572.6 | Upgrade
|
| Accounts Payable | 3.16 | 5.49 | 8.27 | 9.51 | 5.05 | 6.41 | Upgrade
|
| Accrued Expenses | 18.44 | 44.1 | 34.56 | 31.3 | 20.19 | 24.05 | Upgrade
|
| Current Portion of Leases | 6.09 | 14.65 | 12.16 | 11.08 | 10.31 | 6.81 | Upgrade
|
| Current Unearned Revenue | 5 | 11.22 | 8.22 | 8.22 | 11.33 | 20.94 | Upgrade
|
| Other Current Liabilities | 29.08 | 1.76 | - | - | - | - | Upgrade
|
| Total Current Liabilities | 61.77 | 77.23 | 63.22 | 60.11 | 46.88 | 58.21 | Upgrade
|
| Long-Term Leases | 13.56 | 20.38 | 24.37 | 32.86 | 16.07 | 19.32 | Upgrade
|
| Long-Term Unearned Revenue | 108.27 | 106.64 | 60.67 | 60.67 | 60.89 | 73.98 | Upgrade
|
| Other Long-Term Liabilities | 4.69 | 3.07 | 1.8 | - | - | 27.5 | Upgrade
|
| Total Liabilities | 188.3 | 207.32 | 150.06 | 153.64 | 123.84 | 179.02 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 1,636 | 1,602 | 1,580 | 1,442 | 1,412 | 1,059 | Upgrade
|
| Retained Earnings | -1,623 | -1,468 | -1,231 | -1,078 | -857.7 | -665.2 | Upgrade
|
| Comprehensive Income & Other | - | 0.27 | 0.2 | -3.6 | -0.49 | -0.05 | Upgrade
|
| Total Common Equity | 13.45 | 134.27 | 349.1 | 360.68 | 553.64 | 393.59 | Upgrade
|
| Shareholders' Equity | 13.45 | 134.27 | 349.1 | 360.68 | 553.64 | 393.59 | Upgrade
|
| Total Liabilities & Equity | 201.75 | 341.59 | 499.15 | 514.32 | 677.48 | 572.6 | Upgrade
|
| Total Debt | 19.65 | 35.03 | 36.54 | 43.95 | 26.38 | 26.14 | Upgrade
|
| Net Cash (Debt) | 146 | 234.88 | 390.6 | 393.43 | 593.54 | 485.64 | Upgrade
|
| Net Cash Growth | -35.57% | -39.87% | -0.72% | -33.72% | 22.22% | 13.45% | Upgrade
|
| Net Cash Per Share | 1.72 | 2.85 | 5.14 | 5.73 | 8.78 | 8.29 | Upgrade
|
| Filing Date Shares Outstanding | 97.62 | 82.98 | 81.81 | 67.47 | 68.46 | 67.24 | Upgrade
|
| Total Common Shares Outstanding | 93.26 | 82.73 | 81.77 | 67.35 | 68.44 | 62.56 | Upgrade
|
| Working Capital | 115.12 | 212.09 | 277.61 | 296.64 | 460.43 | 360.88 | Upgrade
|
| Book Value Per Share | 0.14 | 1.62 | 4.27 | 5.36 | 8.09 | 6.29 | Upgrade
|
| Tangible Book Value | 13.45 | 134.27 | 349.1 | 360.68 | 553.64 | 393.59 | Upgrade
|
| Tangible Book Value Per Share | 0.14 | 1.62 | 4.27 | 5.36 | 8.09 | 6.29 | Upgrade
|
| Machinery | 23.01 | 30.88 | 26.37 | 25.55 | 22.72 | 19.17 | Upgrade
|
| Construction In Progress | 0.08 | 0.83 | 2.06 | 1.57 | 1.53 | 0.86 | Upgrade
|
| Leasehold Improvements | 8.4 | 11.75 | 9.65 | 9.76 | 8.16 | 4.97 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.